<DOC>
	<DOCNO>NCT02140684</DOCNO>
	<brief_summary>This study compare absolute relative effectiveness manage real-life asthma without use NIOX MINO® NIOX Flex® measure exhale nitric oxide ( eNO ) marker underlie airway inflammation guide appropriate management . As exhaled nitric oxide respond rapidly environmental change act marker underlying inflammation propose incorporate eNO monitoring routine asthma management treatment allow strategy accurately tailor patient need , increase probability good asthma control .</brief_summary>
	<brief_title>Exhaled Nitric Oxide Asthma Management</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>1 . Aged : 680 year 2 . Evidence active asthma ( diagnostic code and/or ≥6 prescription asthma therapy time record ) 3 . Evidence current asthma treatment ( ≥2 asthma prescription baseline year outcome year ) 4 . Have least one year uptostandard ( UTS ) baseline data least one year UTS outcome data ( follow IPD ) 1 . Had COPD read code time ; and/or 2 . Had chronic respiratory disease , except asthma , time ; and/or 3 . Patients maintenance oral steroid baseline year 4 . Smoker exsmoker age 60</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Real-world</keyword>
	<keyword>observational</keyword>
	<keyword>Nitric oxide</keyword>
	<keyword>Inhaled corticosteroid</keyword>
	<keyword>UK</keyword>
</DOC>